drugset / Trial / NCT00649259

Food Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg

NCT00649259

Phase 1 Completed 39 enrolled Mylan Pharmaceuticals Inc
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study was to investigate the single-dose relative bioavailability of Mylan's oxybutynin chloride extended-release tablets to ALZA's Ditropan XL® tablets following an oral, single 20 mg (2 x 10 mg) dose under fed conditions.

Timeline

Start
2002-10
Primary completion
2002-11
Completion
2002-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Oxybutynin Small molecule 20 mg Oral

Indications

No indication recorded.